Abstract: Disclosed herein is a financial card system. The system includes a communications device on which a non-contact integrated circuit chip is installed; and an authentication terminal having a reader/writer allowing reading/writing information on the communications device and capable of transmission and reception of information with the communications device through the reader/writer. The communications device has a storage block, a common area information transmission block, and an individual area information transmission block. The reader/writer of the authentication terminal has a storage block, a common area information reception block, and an individual area information reception block.

Abstract: The present invention provides a method of improving or treating inflammatory bowel disease through suppression of the expression of inflammatory cytokines based on the action mechanism of suppression of NF-?B activation by administering feruloyl serotonin to a subject in need of treatment of inflammatory bowel disease. The feruloyl serotonin of the present invention can be administered as a pharmaceutical agent or a food.

Abstract: A communication device, a remote server, a terminal device, a financial card issue system, a financial card authentication system, and a computer-readable storage medium for authenticating card information. In one embodiment, a communication device incorporates an IC chip. The communication device may be connected to a financial institution server and a remote server through a network. The communication device may include a card issue request portion for requesting the financial institution server to issue a first card; a card information write request portion for receiving first card information corresponding to the first card from the financial institution server and requesting the remote server to write the first card information; and a storage portion including a first individual area, a second individual area, and a common area.

Abstract: The present invention provides an oral composition which can more effectively prevent or improve functional gastrointestinal disorders, particularly upper gastrointestinal dysfunction, specifically functional dyspepsia, and is highly safe and suitable for long-term ingestion. The oral composition of the present invention contains sodium glutamate and arginine hydrochloride at a molar ratio of 1:1. The aforementioned composition can be provided as an agent for the prophylaxis or improvement of functional gastrointestinal disorder, and can also be provided in a food or drink.

Abstract: Disclosed herein is a financial card system. The system includes a communications device on which a non-contact integrated circuit chip is installed; and an authentication terminal having a reader/writer allowing reading/writing information on the communications device and capable of transmission and reception of information with the communications device through the reader/writer. The communications device has a storage block, a common area information transmission block, and an individual area information transmission block. The reader/writer of the authentication terminal has a storage block, a common area information reception block, and an individual area information reception block.

Abstract: Disclosed herein is a financial card system. The system includes a communications device on which a non-contact integrated circuit chip is installed; and an authentication terminal having a reader/writer allowing reading/writing information on the communications device and capable of transmission and reception of information with the communications device through the reader/writer. The communications device has a storage block, a common area information transmission block, and an individual area information transmission block. The reader/writer of the authentication terminal has a storage block, a common area information reception block, and an individual area information reception block.

Abstract: The present invention provides a method of improving or preventing various conditions through suppression of the expression of inflammatory cytokines based on the action mechanism of suppression of NF-?B activation. The present invention provides a composition for suppressing NF-?B activation, containing a serotonin derivative such as feruloyl serotonin (N-feruloyl serotonin) and p-coumaroyl serotonin (N-(p-coumaroyl)serotonin), a composition for suppressing the expression of VCAM-1 and/or MCP-1 via NF-?B, containing the serotonin derivative and an anti-inflammatory composition containing the serotonin derivative. The composition of the present invention can be used as a pharmaceutical agent or a food.

Abstract: A communication device, a remote server, a terminal device, a financial card issue system, a financial card authentication system, and a computer-readable storage medium for authenticating card information. In one embodiment, a communication device incorporates an IC chip. The communication device may be connected to a financial institution server and a remote server through a network. The communication device may include a card issue request portion for requesting the financial institution server to issue a first card; a card information write request portion for receiving first card information corresponding to the first card from the financial institution server and requesting the remote server to write the first card information; and a storage portion including a first individual area, a second individual area, and a common area.

Abstract: Disclosed herein is a financial card system. The system includes a communications device on which a non-contact integrated circuit chip is installed; and an authentication terminal having a reader/writer allowing reading/writing information on the communications device and capable of transmission and reception of information with the communications device through the reader/writer. The communications device has a storage block, a common area information transmission block, and an individual area information transmission block. The reader/writer of the authentication terminal has a storage block, a common area information reception block, and an individual area information reception block.

Abstract: A compound 1-formyl-N-(2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl)) ethyl isonipecotic acid amide or an analog thereof or a pharmaceutically acceptable salt thereof provides a therapeutic agent for treating a patient suffering from intermittent claudication.

Abstract: A compound 1-formyl-N-(2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl)) ethyl isonipecotic acid amide or an analog thereof or a pharmaceutically acceptable salt thereof provides a therapeutic agent for treating a patient suffering from intermittent claudication.

Abstract: A thrombolytic drug containing cyproheptadine, a compound of the following formula or a salt thereof as the active ingredient is provided. This thrombolytic drug has a function of accelerating the release of a tissue plasminogen activator (t-PA), while exerting no effect on the release of type-1 plasminogen activator inhibitor (PAI-1) which deactivates t-PA or reducing the release thereof. wherein n represents an integer of 2 or 3, Y represents a hydrogen atom or halogen atom, and X represents a formyl group, acetyl group or hydrogen atom.

Abstract: Disclosed is a pharmaceutical composition for use in the treatment of diabetic neuropathy, which comprises a piperidine derivative represented by the following general formula (1) or a pharmaceutically acceptable salt thereof as an effective ingredient: wherein n is an integer of 2 of 3, Y is a hydrogen atom or halogen atom, and X is a formyl group, acetyl group or hydrogen atom.